Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353722 | 0.87 | YTHDC1 (0.72) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL20275400 | 0.87 | YTHDC1 (0.72) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL244963 | 0.87 | YTHDC1 (0.72) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL10310499 | 0.86 | CYP2C19 (0.58) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL179599 | 0.85 | YTHDC1 (0.59) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL112713 | 0.85 | YTHDC1 (0.62) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL935632 | 0.85 | YTHDC1 (0.59) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL29878593 | 0.85 | YTHDC1 (0.59) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL4151824 | 0.83 | YTHDC1 (0.66) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A | |
| SCHEMBL5724007 | 0.81 | YTHDC1 (0.56) | YTHDC1CYP2C19MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022124859-A1 | 1'-HOMOADENOSNE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPOADIPONECTINEMIA-ASSOCIATED DISEASES OR PSORIASIS, CONTAINING SAME AS ACTIVE INGREDIENT | 서울대학교산학협력단 | 2022-06-16 | — | — | WO | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1515970-B1 | ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20060100429-A1 | Alkynylpurine compounds and production methods thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-11 | — | — | US | disclosed |
| CN-1662536-A | Alkynylpurine compounds and production methods thereof | SUMITOMO CHEMICAL CO (JP) | 2005-08-31 | — | — | CN | disclosed |
| EP-1515970-A1 | ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106458-A1 | ALKYNYLPURINE COMPOUNDS AND PRODUCTION METHODS THEREOF | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | YTHDC1 4127/4885CYP2C19 88/4885MEN1 1262/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | YTHDC1 4875/4885CYP2C19 1585/4885MEN1 892/4885 |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | YTHDC1 4127/4885CYP2C19 88/4885MEN1 1262/4885 |
| US-20060100429-A1 | Alkynylpurine compounds and production methods thereof | TPMT, IMPDH1, IMPDH2 | YTHDC1 1057/4885CYP2C19 937/4885MEN1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.